Phase Forward Introduces New Version of Phase Forward(TM) Clinical Development Center

Phase Forward Introduces New Version of Phase Forward(TM) Clinical Development Center
Provides a Centralized Solution to Streamline Data Preparation for Analysis Including New Integration with InForm(TM) 

WALTHAM, Mass., May 04, 2010 (BUSINESS WIRE) -- Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced the latest version of the Phase Forward(TM) Clinical Development Center (CDC), a centralized solution for integrating, managing and analyzing clinical information. This new release focuses on streamlining the preparation of clinical trial data for analysis by providing a flexible and effective workflow to track, manage and reconcile data discrepancies that can be found within different data sources.

The release also offers "out-of-the-box" integration with the Phase Forward InForm(TM) global trial management (GTM) electronic data capture (EDC) solution. The integration automates study set-up and delivery of InForm data to the CDC -- significantly reducing data handling time and effort. The integration also provides data managers with direct links back to InForm, enabling them to simplify the process of reviewing study source data or issuing queries.

"Our customers are looking for a centralized solution to efficiently process the increasing amounts of data collected within clinical trials," said Martin Young, Phase Forward Senior Vice President, Integration and Product Strategy. "This new version of Phase Forward CDC delivers a means to more expeditiously and effectively manage this process. The enhanced integration with InForm extends this benefit, giving our customers a way to leverage their existing investments by providing even greater levels of automation and efficiency."

Demands on data managers and biostatisticians to prepare and "clean" data for analysis continue to grow as today's increasingly complex and distributed clinical trials generate unprecedented amounts of electronic information, including patient and lab data, images, statistical programs, plans and other supporting documents. The Phase Forward CDC application helps data managers more efficiently load, transform and reconcile data -- streamlining workflows and improving the readiness of new datasets for interim analysis. The combination of this new functionality with the existing open systems approach, providing the ability to integrate data from multiple systems providers, and the powerful automated traceability and control capabilities of the CDC enables sponsors to better manage, track and ensure analysis is current and accurate.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and acceptance of Phase Forward's products, features of Phase Forward products that are not believed to be available in competing products, and the benefits to customers from the use of such products. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, Phase Forward's inability to convince current and potential customers to order its products, the failure of customers to realize benefits from the use of these products, changes in industry standards, changes in the manner in which Phase Forward customers conduct business, and changes in or introduction of competitive products. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.

SOURCE: Phase Forward


Phase Forward
Elaine Maynard, 781-902-4371
[email protected]
or
CHEN PR, Inc.
Randy Wambold, 781-672-3119
[email protected]

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.